EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated
New Drug Application colchicine capsules, 0.6mg. Aurobindo Pharma’s colchicine capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Mitigare Capsules manufactured by Hikma International Pharmaceuticals LLC.
Colchicine capsules are indicated prophylaxis of gout flares in adults.
Colchicine capsules has an estimated market size of US $55 Million for the twelve months ending Feb 2024, as per IQVIA.
